{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:02:31Z","timestamp":1792544551753,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaad.2018.06.046","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T13:52:46Z","timestamp":1530625966000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial"],"prefix":"10.1016","volume":"80","author":[{"given":"Allard R.J.V.","family":"Vossen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B.A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessel H.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol P.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.06.046_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.06.046_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40257-017-0280-2","article-title":"Assessing pruritus in hidradenitis suppurativa: a cross-sectional study","volume":"18","author":"Vossen","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib3","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2018.06.046_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.046_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.06.046_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13543784.2018.1412430","article-title":"Investigational drugs in clinical trials for hidradenitis suppurativa","volume":"27","author":"Theut Riis","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2018.06.046_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","volume":"75","author":"Bissonnette","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2018.06.046_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in\u00a0vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaad.2018.06.046_bib12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.064691","volume":"310","author":"Claveau","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2018.06.046_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jlb.63.1.101","article-title":"Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production","volume":"63","author":"Eigler","year":"1998","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaad.2018.06.046_bib14","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.06.046_bib15","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical rResponse (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.046_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib18","doi-asserted-by":"crossref","first-page":"87ps24","DOI":"10.1126\/scitranslmed.3001628","article-title":"Breaking free of sample size dogma to perform innovative translational research","volume":"3","author":"Bacchetti","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2018.06.046_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","article-title":"Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex\u00a0vivo study","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1alpha for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.06.046_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.046_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.06.046_bib24","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2018.06.046_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218322023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218322023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:51:40Z","timestamp":1759272700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218322023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0190962218322023"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.046","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734118039.793558175","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}